Follow our live coverage of the FDA’s Psychopharmacologic Drugs Advisory Committee meeting to review Lykos Therapeutics’ MDMA-assisted therapy for PTSD. Our Founder & Editor, Josh Hardman, will share updates throughout the day.
Yesterday, ICER’s independent appraisal committee, the New England CEPAC, met to discuss the effectiveness of Lykos Therapeutics’ MDMA-assisted therapy for PTSD. Here, we review the notable moments and comments.
Here, we review most (but not all) of the public comments submitted to the docket associated with next Tuesday’s meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee to review Lykos Therapeutics’ MDMA-assisted therapy for PTSD.
Next week, the FDA’s Psychopharmalogic Drugs Advisory Committee will meet to discuss Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application. Here’s what to expect.
A CaaMTech & ASRI Collaboration • GH Research & Beckley Psytech: An Update • CaaMTech Grows Tryptamine Patent Portfolio • Atai Sees Two New Allowances to Support DMT Program • Browse the Interactive Psychedelics Patent Database for April 2024